Study shows mycelium boosts disease resistance in Atlantic salmon

Responsible Seafood Advocate

MycoFence® β-glucan enhances disease resistance in Atlantic salmon

Atlantic salmon
New research shows MycoFence® β-glucan enhances disease resistance in Atlantic salmon more effectively than yeast-based options, benefiting aquaculture practices. Photo credit: Onda.

New research reveals that β-glucan from Aspergillus niger mycelium, branded as Mycofence®, significantly enhances disease resistance in Atlantic salmon, outperforming commercial yeast β-glucan in combating ulcerative diseases.

MycoFence® is an organic immunity booster that’s rich in high-quality beta. Derived from mycelium, it’s an eco-friendly and sustainable resource.

“Our research clearly demonstrates that MycoFence®, a novel β-glucan derived from Aspergillus niger, significantly improves the immune response and survival rates of Atlantic salmon during ulcerative disease outbreaks,” said Dr. Fabio Zanuzzo, lead researcher. “These findings provide a promising alternative to commercial yeast β-glucan and can greatly benefit aquaculture practices.”

Onda, a prominent contract research organization specializing in aquatic animal health, unveiled the groundbreaking research findings in partnership with Citribel, a Belgian producer of citric acid and mycelium. The study involved feeding Atlantic salmon with diets containing different levels of MycoFence® and commercial yeast β-glucan. Following a five-week feeding phase, the fish underwent an immersion challenge with T. maritimum or M. viscosa. Growth performance, mortality rates, lesion scores, hematology and immune markers were analyzed.

Ad for [membership]

Findings reveal that salmon fed with Mycofence® exhibited significantly higher survival rates compared to those fed with commercial yeast-derived β-glucan, with no difference from the control group. Mycofence® also triggered a notable up-regulation of the cr3 transcript, essential for immune response and β-glucan recognition, shedding light on its enhanced disease resistance mechanisms.

Further, the results show MycoFence® reduced mortality from T. maritimum infections by 42.6 percent and from M. viscosa outbreaks by 31 percent, outperforming the commercial yeast β-glucan. Importantly, Mycofence® did not affect the salmon’s growth performance, with no significant differences in weight or growth between diet groups.

@GSA_Advocate

Now that you've reached the end of the article ...

… please consider supporting GSA’s mission to advance responsible seafood practices through education, advocacy and third-party assurances. The Advocate aims to document the evolution of responsible seafood practices and share the expansive knowledge of our vast network of contributors.

By becoming a Global Seafood Alliance member, you’re ensuring that all of the pre-competitive work we do through member benefits, resources and events can continue. Individual membership costs just $50 a year.

Not a GSA member? Join us.

Support GSA and Become a Member